Powered 500 · 2026POWEREDS. 183 of 500
Oyler co-founded BeOne Medicines and steered its BTK inhibitor Brukinsa to beat the prior standard of care in head-to-head trials — a scientific win rare enough to vault a biotech into genuine competition with the world's largest pharma companies across dozens of countries.
John V.
Oyler is Co-Founder, Chairman, and CEO of BeOne Medicines (formerly BeiGene), the global oncology biotechnology company whose BTK inhibitor Brukinsa has achieved leadership status in multiple hematologic cancer indications. He was named the 2025 EY Entrepreneur of the Year National Health Award winner. BeOne operates one of the largest clinical-stage oncology pipelines and runs trials in dozens of countries. Oyler previously co-founded BioDuro.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
